KYMR
Price
$44.91
Change
+$0.01 (+0.02%)
Updated
Jul 15 closing price
Capitalization
3.15B
16 days until earnings call
NUVL
Price
$82.95
Change
-$1.64 (-1.94%)
Updated
Jul 15 closing price
Capitalization
5.96B
22 days until earnings call
Interact to see
Advertisement

KYMR vs NUVL

Header iconKYMR vs NUVL Comparison
Open Charts KYMR vs NUVLBanner chart's image
Kymera Therapeutics
Price$44.91
Change+$0.01 (+0.02%)
Volume$1.06M
Capitalization3.15B
Nuvalent
Price$82.95
Change-$1.64 (-1.94%)
Volume$695.54K
Capitalization5.96B
KYMR vs NUVL Comparison Chart in %
Loading...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KYMR vs. NUVL commentary
Jul 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KYMR is a Buy and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 16, 2025
Stock price -- (KYMR: $44.91 vs. NUVL: $82.95)
Brand notoriety: KYMR and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KYMR: 110% vs. NUVL: 125%
Market capitalization -- KYMR: $3.15B vs. NUVL: $5.96B
KYMR [@Biotechnology] is valued at $3.15B. NUVL’s [@Biotechnology] market capitalization is $5.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KYMR’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • KYMR’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both KYMR and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KYMR’s TA Score shows that 5 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • KYMR’s TA Score: 5 bullish, 3 bearish.
  • NUVL’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, KYMR is a better buy in the short-term than NUVL.

Price Growth

KYMR (@Biotechnology) experienced а +2.51% price change this week, while NUVL (@Biotechnology) price change was +5.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.

Reported Earning Dates

KYMR is expected to report earnings on Oct 30, 2025.

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.96B) has a higher market cap than KYMR($3.15B). KYMR YTD gains are higher at: 11.633 vs. NUVL (5.966). KYMR has higher annual earnings (EBITDA): -232.67M vs. NUVL (-322.59M). NUVL has more cash in the bank: 1.07B vs. KYMR (463M). KYMR has higher revenues than NUVL: KYMR (58.9M) vs NUVL (0).
KYMRNUVLKYMR / NUVL
Capitalization3.15B5.96B53%
EBITDA-232.67M-322.59M72%
Gain YTD11.6335.966195%
P/E RatioN/AN/A-
Revenue58.9M0-
Total Cash463M1.07B43%
Total Debt86.3MN/A-
TECHNICAL ANALYSIS
Technical Analysis
KYMRNUVL
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIEUX44.34N/A
N/A
Fidelity Europe
LGIEX20.79N/A
N/A
Franklin International Equity I
WWSIX23.30N/A
N/A
Keeley Small Cap Fund Institutional
MMUHX24.05N/A
N/A
MFS Utilities R3
HDGVX36.43N/A
N/A
Hartford Dividend and Growth R6

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with CGON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-1.94%
CGON - NUVL
56%
Loosely correlated
-3.67%
CRNX - NUVL
52%
Loosely correlated
-3.60%
ABCZF - NUVL
51%
Loosely correlated
N/A
IDYA - NUVL
51%
Loosely correlated
-5.09%
KYMR - NUVL
50%
Loosely correlated
+0.02%
More